Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3995 add-on therapy in type 2 diabetic nephropathy with albuminuria
2012-002481-12Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing MT-3995 add-on arm with Placebo add-on arm (2 arms). Primary endpoints: Change in urine albumin-to-creatinine ratio (UACR), Pharmacodynamic outcomes and 2 more. Started Jul 2012; status: completed.
02
Drugs
apararenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2012-002481-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002481-12.